Optima Medical Innovations Corp.

Optima Medical Innovations Corp. produces and sells hemp-based cannabidiol (CBD) products in Canada and internationally. It offers industrial hemp-derived CBD oil, airless metered pens, capsules, topicals, and tinctures. The company also operates multidisciplinary pain clinics, which focuses on the treatment of chronic pain, including comprehensive, medical, and interventional pain management; independent medical evaluations; physiotherapy and chiropractic care; and medical cannabis and platelet rich plasma therapy, as well as mindfulness teaching. It has a research agreement with the Ryerson University for medical cannabis research and new medical grade products development. The company was formerly known as Tree of Knowledge International Corp. and changed its name to Optima Medical Innovations Corp. in November 2021. Optima Medical Innovations Corp. is based in Toronto, Canada.

Optima Medical Innovations Corp. trades as TOKIF on OTC. The company is classified in Healthcare / Medical - Care Facilities and reports in USD.

The current profile places the business in Medical - Care Facilities. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Optima Medical Innovations Corp. can be compared against peers such as Global Cord Blood Corporation, Grown Rogue International Inc., Lumos Diagnostics Holdings Limited, Satellos Bioscience Inc., Orexo AB (publ), Pacific Edge Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $101.43M, beta of -0.26, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

TOKIF currently shows total debt of N/A and beta of -0.26. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.tokicorp.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.